Home blood sampling to tailor lung cancer drug doses
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new way to monitor your cancer treatment by measuring drug levels using a finger-prick blood sample you can collect at home. The goal is to help doctors personalize your medication dose without requiring frequent clinic visits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of non-small cell lung cancer (NSCLC).
- You must be currently receiving one of these treatments: docetaxel, paclitaxel, alectinib, or lorlatinib.
- You must be able to collect a small blood sample yourself (finger prick) at home, or have someone to help you do it.
- You must have a stable place at home (or another suitable location) where you can collect the sample and, if needed, receive a home nurse visit.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects blood and tissue samples from people with non-small cell lung cancer (NSCLC) either before or after treatment. It aims to help researchers learn more about how tumors respond, especially in cancers with specific genetic changes or after certain pre-surgery therapies.
This study checks whether “liquid biopsies” (blood tests) can help monitor advanced non-small-cell lung cancer. It looks at different patient groups based on timing and tumor features, aiming to make cancer tracking easier and less invasive.
This trial checks whether a blood test that looks for cancer DNA can help guide and monitor treatment in people with advanced non-small cell lung cancer (NSCLC). It may help your team spot treatment response or changes earlier, so care can be adjusted appropriately.
This trial collects blood and tumor samples from people newly diagnosed with small cell lung cancer to study how genetic markers can predict treatment success and monitor disease over time.
This trial is testing a personalized treatment for non-small cell lung cancer that uses a patient's own immune cells to fight the tumor. It may help patients with early or advanced stages of the disease.
This trial uses advanced gene sequencing technology on blood and tumor tissue samples from people with non-small cell lung cancer. The goal is to see if this testing can help doctors better predict which treatments will work and detect if the cancer comes back early.
Hear when a new Non-Small Cell Lung Cancer (MeSH Term: Carcinoma, Non-Small-Cell Lung) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.